Contact
Contact
Registered addresses
SynOx Therapeutics Limited
3 Dublin Landings, North Wall Quay
Dublin 1
D01 C4EO
Ireland
SynOx Therapeutics UK Limited
John Eccles House
Robert Robinson Avenue
Oxford Science Park
Oxford
OX4 4GP
UK
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
© SynOx Therapeutics. Last Revised: July 2022.
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
© SynOx Therapeutics. Last Revised: July 2022.